Patents by Inventor Nicholas F. Landolfi

Nicholas F. Landolfi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
    Publication number: 20200031929
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: October 10, 2019
    Publication date: January 30, 2020
    Inventors: Marna WILLIAMS, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 10442859
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: October 15, 2019
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
    Publication number: 20160002335
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: September 22, 2015
    Publication date: January 7, 2016
    Inventors: Marna WILLIAMS, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 9175081
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: November 3, 2015
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • Antibodies to CD122
    Patent number: 9028830
    Abstract: The invention provides monoclonal antibodies that specifically bind to CD122, which is one component of receptors for IL-2 and IL-15. The monoclonal antibodies have the capacity for substantial inhibition of both IL-2 and IL-15 mediated functions by inhibiting binding of these cytokines to their receptors. The monoclonal antibodies can be used for inhibiting undesired immune responses or treatment of cancer, among other applications.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: May 12, 2015
    Assignee: JN Biosciences, LLC
    Inventors: J. Yun Tso, Naoya Tsurushita, Nicholas F. Landolfi, Shankar Kumar
  • THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
    Publication number: 20140065063
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: May 15, 2013
    Publication date: March 6, 2014
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8461306
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: June 11, 2013
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8444980
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: May 21, 2013
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8445646
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: May 21, 2013
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8436146
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: May 7, 2013
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8349330
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: January 8, 2013
    Assignee: Abbott Biotherapeutics Corp.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
    Publication number: 20120070440
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: July 1, 2011
    Publication date: March 22, 2012
    Applicant: ABBOTT BIOTHERAPEUTICS CORP.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
    Publication number: 20120064083
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: June 30, 2011
    Publication date: March 15, 2012
    Applicant: ABBOTT BIOTHERAPEUTICS CORP.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
    Publication number: 20120064068
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: July 1, 2011
    Publication date: March 15, 2012
    Applicant: Abbott Biotherapeutics Corp.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
    Publication number: 20120064067
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: July 1, 2011
    Publication date: March 15, 2012
    Applicant: ABBOTT BIOTHERAPEUTICS CORP.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Liu
  • THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
    Publication number: 20120064069
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Application
    Filed: July 1, 2011
    Publication date: March 15, 2012
    Applicant: ABBOTT BIOTHERAPEUTICS CORP.
    Inventors: Marna WILLIAMS, J. Yun Tso, Nicholas F. Landolfi, David B. Powers, Gao Llu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8133981
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: March 13, 2012
    Assignee: Abbott Biotherapeutics Corp.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8088898
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: January 3, 2012
    Assignee: Abbott Biotherapeutics Corp.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
  • ANTIBODIES TO CD122
    Publication number: 20110250213
    Abstract: The invention provides monoclonal antibodies that specifically bind to CD122, which is one component of receptors for IL-2 and IL-15. The monoclonal antibodies have the capacity for substantial inhibition of both IL-2 and IL-15 mediated functions by inhibiting binding of these cytokines to their receptors. The monoclonal antibodies can be used for inhibiting undesired immune responses or treatment of cancer, among other applications.
    Type: Application
    Filed: April 7, 2011
    Publication date: October 13, 2011
    Applicant: JN Biosciences, LLC
    Inventors: J. Yun Tso, Naoya Tsurushita, Nicholas F. Landolfi, Shankar Kumar
  • Therapeutic use of anti-CS1 antibodies
    Patent number: 8008450
    Abstract: The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
    Type: Grant
    Filed: November 2, 2009
    Date of Patent: August 30, 2011
    Assignee: Abbott Biotherapeutics Corp.
    Inventors: Marna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu